{"id":"lm-302-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"LM-302 Injection works by binding to its target, thereby modulating its activity and exerting its therapeutic effect.","oneSentence":"LM-302 Injection is a monoclonal antibody targeting a specific molecular target.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:13.168Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06351020","phase":"PHASE3","title":"LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","startDate":"2024-06-24","conditions":"Locally Advanced or Metastatic GC and GCJ Adenocarcinoma","enrollment":387},{"nctId":"NCT07385703","phase":"PHASE3","title":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2026-03","conditions":"Adenocarcinoma","enrollment":752},{"nctId":"NCT05161390","phase":"PHASE1, PHASE2","title":"Study of LM-302 in Patients With Advance Solid Tumors","status":"COMPLETED","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","startDate":"2021-11-26","conditions":"Advanced Solid Tumor","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ClAUDIN 18.2-ADC"],"phase":"phase_3","status":"active","brandName":"LM-302 Injection","genericName":"LM-302 Injection","companyName":"LaNova Medicines Zhejiang Co., Ltd.","companyId":"lanova-medicines-zhejiang-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LM-302 Injection is a monoclonal antibody targeting a specific molecular target. Used for Treatment of metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}